Kevin O'Neil

Kevin O'Neil has worked in various roles in the finance and investor relations departments of different companies. Kevin started their career as a Financial Analyst at Stanley Black & Decker, Inc. in June 2013. In 2014, they joined PAREXEL as a Financial Analyst II, later becoming a Senior Finance Business Partner and then a Principal Finance Business Partner. In 2018, they moved to Alexion Pharmaceuticals, Inc. where they held roles as Manager of R&D Finance, Senior Manager of Investor Relations, and finally Associate Director of Investor Relations. Currently, they are employed at ImmunoGen, Inc. as the Associate Director of R&D Finance, with a promotion to Director expected in March 2023.

Kevin O'Neil obtained a Bachelor of Science degree in Finance from the University of Connecticut in 2013. Kevin furthered their education by completing a Master of Business Administration (M.B.A.) in Leadership & Management at Bentley University from 2015 to 2018.